Trial Profile
Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Bendamustine; Gemcitabine; Romidepsin
- Indications Follicular lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Acronyms ORACLE
- 13 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Jun 2024.
- 24 May 2023 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 13 Dec 2022 Primary endpoint has not been met (Progression Free Survival (PFS)) , according to presented at the 64th American Society of Hematology Annual Meeting and Exposition